42 related articles for article (PubMed ID: 38501405)
1. [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
[TBL] [Abstract][Full Text] [Related]
2. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
3. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
4. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Blinova E; Roshchin D; Kogan E; Samishina E; Demura T; Deryabina O; Suslova I; Blinov D; Zhdanov P; Osmanov U; Nelipa M; Kaprin A
Cells; 2019 May; 8(6):. PubMed ID: 31159302
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
7. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.
Klement JD; Redd PS; Lu C; Merting AD; Poschel DB; Yang D; Savage NM; Zhou G; Munn DH; Fallon PG; Liu K
Cancer Cell; 2023 Mar; 41(3):620-636.e9. PubMed ID: 36917954
[TBL] [Abstract][Full Text] [Related]
8. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.
Zheng J; Huang J; Zhang L; Wang M; Xu L; Dou X; Leng X; Fang M; Sun Y; Wang Z
Biomater Res; 2023 Feb; 27(1):9. PubMed ID: 36759928
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway.
Luo D; Zeng X; Zhang S; Li D; Cheng Z; Wang Y; Long J; Hu Z; Long S; Zhou J; Zhang S; Zeng Z
J Cell Mol Med; 2023 Feb; 27(3):456-469. PubMed ID: 36651490
[TBL] [Abstract][Full Text] [Related]
11. The primordial differentiation of tumor-specific memory CD8
Huang Q; Wu X; Wang Z; Chen X; Wang L; Lu Y; Xiong D; Liu Q; Tian Y; Lin H; Guo J; Wen S; Dong W; Yang X; Yuan Y; Yue Z; Lei S; Wu Q; Ran L; Xie L; Wang Y; Gao L; Tian Q; Zhou X; Sun B; Xu L; Tang Z; Ye L
Cell; 2022 Oct; 185(22):4049-4066.e25. PubMed ID: 36208623
[TBL] [Abstract][Full Text] [Related]
12. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.
Reda M; Ngamcherdtrakul W; Nelson MA; Siriwon N; Wang R; Zaidan HY; Bejan DS; Reda S; Hoang NH; Crumrine NA; Rehwaldt JPC; Bindal A; Mills GB; Gray JW; Yantasee W
Nat Commun; 2022 Jul; 13(1):4261. PubMed ID: 35871223
[TBL] [Abstract][Full Text] [Related]
13. The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.
Wang G; Zhou X; Guo Z; Huang N; Li J; Lv Y; Han L; Zheng W; Xu D; Chai D; Li H; Li L; Zheng J
Cancer Biol Ther; 2022 Dec; 23(1):150-162. PubMed ID: 35130111
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]